Perrigo Company plc Operating Expenses
Perrigo Company plc (PRGO) reported Operating Expenses of $290.50 million for the 3-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-05
- Perrigo Company plc operating expenses for the quarter ending 2026-06-27 was $290.50M, a 8.50% decline year-over-year.
- Perrigo Company plc operating expenses for the quarter ending 2026-03-28 was $697.80M, a 102.03% increase year-over-year.
- Perrigo Company plc operating expenses for the quarter ending 2025-12-31 was $1.65B, a 507.03% increase year-over-year.
- Perrigo Company plc operating expenses for the quarter ending 2025-09-27 was $304.50M, a 6.02% decline year-over-year.
- Perrigo Company plc operating expenses for fiscal 2025 was $2.62B, a 83.01% increase from fiscal 2024.
- Perrigo Company plc operating expenses for fiscal 2024 was $1.43B, a 6.46% decline from fiscal 2023.
- Perrigo Company plc operating expenses for fiscal 2023 was $1.53B, a 11.04% increase from fiscal 2022.
- Perrigo Company plc operating expenses for fiscal 2022 was $1.38B, a 36.86% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-27 | $290.50M 10-Q · filed 2026-08-05 | $988.30M 10-Q · filed 2026-08-05 | $2.64B derived: sum of 3 quarters · filed 2026-08-05 | $2.94B derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-28 | $697.80M 10-Q · filed 2026-05-06 | $2.35B derived: sum of 2 quarters · filed 2026-05-06 | $2.65B derived: sum of 3 quarters · filed 2026-05-06 | $2.97B derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $1.65B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.95B derived: sum of 2 quarters · filed 2026-02-26 | $2.27B derived: sum of 3 quarters · filed 2026-08-05 | $2.62B 10-K · filed 2026-02-26 | ||||
| 2025-09-27 | $304.50M 10-Q · filed 2025-11-05 | $622.00M derived: sum of 2 quarters · filed 2026-08-05 | $967.40M 10-Q · filed 2025-11-05 | $1.24B derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-28 | $317.50M 10-Q · filed 2026-08-05 | $662.90M 10-Q · filed 2026-08-05 | $934.60M derived: sum of 3 quarters · filed 2026-08-05 | $1.26B derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-29 | $345.40M 10-Q · filed 2026-05-06 | $617.10M derived: sum of 2 quarters · filed 2026-05-06 | $941.10M derived: sum of 3 quarters · filed 2026-05-06 | $1.36B derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $271.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $595.70M derived: sum of 2 quarters · filed 2026-02-26 | $1.02B derived: sum of 3 quarters · filed 2026-02-26 | $1.43B 10-K · filed 2026-02-26 | ||||
| 2024-09-28 | $324.00M 10-Q · filed 2025-11-05 | $745.20M derived: sum of 2 quarters · filed 2025-11-05 | $1.16B 10-Q · filed 2025-11-05 | $1.60B derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-29 | $421.20M 10-Q · filed 2025-08-06 | $834.10M 10-Q · filed 2025-08-06 | $1.28B derived: sum of 3 quarters · filed 2026-02-26 | $1.63B derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-03-30 | $412.90M 10-Q · filed 2025-05-07 | $855.80M derived: sum of 2 quarters · filed 2026-02-26 | $1.20B derived: sum of 3 quarters · filed 2026-02-26 | $1.58B derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2023-12-31 | $442.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $792.00M derived: sum of 2 quarters · filed 2026-02-26 | $1.16B derived: sum of 3 quarters · filed 2026-02-26 | $1.53B 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | $349.10M 10-Q · filed 2024-11-06 | $720.30M derived: sum of 2 quarters · filed 2024-11-06 | $1.09B 10-Q · filed 2024-11-06 | $1.44B derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2023-07-01 | $371.20M 10-Q · filed 2024-08-02 | $736.50M 10-Q · filed 2024-08-02 | $1.09B derived: sum of 3 quarters · filed 2025-02-28 | $1.42B derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2023-04-01 | $365.30M 10-Q · filed 2024-05-07 | $716.90M derived: sum of 2 quarters · filed 2025-02-28 | $1.05B derived: sum of 3 quarters · filed 2025-02-28 | $1.43B derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2022-12-31 | $351.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $681.40M derived: sum of 2 quarters · filed 2025-02-28 | $1.06B derived: sum of 3 quarters · filed 2025-02-28 | $1.38B 10-K · filed 2025-02-28 | ||||
| 2022-10-01 | $329.80M 10-Q · filed 2023-11-07 | $708.80M derived: sum of 2 quarters · filed 2023-11-07 | $1.02B 10-Q · filed 2023-11-07 | $1.34B derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-07-02 | $379.00M 10-Q · filed 2023-08-08 | $695.10M 10-Q · filed 2023-08-08 | $1.01B derived: sum of 3 quarters · filed 2024-02-27 | $908.90M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-04-02 | $316.10M 10-Q · filed 2023-05-09 | $631.80M derived: sum of 2 quarters · filed 2024-02-27 | $529.90M derived: sum of 3 quarters · filed 2024-02-27 | $1.00B derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2021-12-31 | $315.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $213.80M derived: sum of 2 quarters · filed 2024-02-27 | $688.70M derived: sum of 3 quarters · filed 2024-02-27 | $1.01B 10-K · filed 2024-02-27 | ||||
| 2021-10-02 | -$101.90M 10-Q · filed 2022-11-08 | $373.00M derived: sum of 2 quarters · filed 2022-11-08 | $690.10M 10-Q · filed 2022-11-08 | $1.04B derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-07-03 | $474.90M 10-Q · filed 2022-08-09 | $792.00M 10-Q · filed 2022-08-09 | $1.14B derived: sum of 3 quarters · filed 2023-02-28 | $1.43B derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-04-03 | $317.00M 10-Q · filed 2022-05-11 | $663.80M derived: sum of 2 quarters · filed 2023-02-28 | $955.00M derived: sum of 3 quarters · filed 2023-02-28 | $1.24B derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2020-12-31 | $346.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $638.00M derived: sum of 2 quarters · filed 2023-02-28 | $922.50M derived: sum of 3 quarters · filed 2023-02-28 | $1.23B 10-K · filed 2023-02-28 | $1.70B 10-K · filed 2021-03-01 | |||
| 2020-09-26 | $291.20M 10-Q · filed 2021-11-12 | $523.60M 10-Q · filed 2020-11-05 | $575.70M derived: sum of 2 quarters · filed 2021-11-12 | $882.90M 10-Q · filed 2021-11-12 | $1.18B 10-Q · filed 2020-11-05 | $1.06B derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-06-27 | $284.50M 10-Q · filed 2021-08-11 | $317.30M 10-Q · filed 2020-08-05 | $591.80M 10-Q · filed 2021-08-11 | $654.80M 10-Q · filed 2020-08-05 | $770.00M derived: sum of 3 quarters · filed 2022-03-01 | $1.13B derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-03-28 | $307.30M 10-Q · filed 2021-05-12 | $337.50M 10-Q · filed 2020-05-05 | $485.50M derived: sum of 2 quarters · filed 2022-03-01 | $843.90M derived: sum of 3 quarters · filed 2022-03-01 | $1.22B derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2019-12-31 | $178.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $536.60M derived: sum of 2 quarters · filed 2022-03-01 | $912.40M derived: sum of 3 quarters · filed 2022-03-01 | $1.26B 10-K · filed 2022-03-01 | $1.57B 10-K · filed 2020-02-27 | |||
| 2019-09-28 | $358.40M 10-Q · filed 2020-11-05 | $734.20M derived: sum of 2 quarters · filed 2020-11-05 | $1.08B 10-Q · filed 2020-11-05 | $1.42B derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-06-29 | $375.80M 10-Q · filed 2020-08-05 | $722.30M 10-Q · filed 2020-08-05 | $1.06B derived: sum of 3 quarters · filed 2021-03-01 | $1.60B derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-03-30 | $346.50M 10-Q · filed 2020-05-05 | $682.00M derived: sum of 2 quarters · filed 2021-03-01 | $1.23B derived: sum of 3 quarters · filed 2021-03-01 | $1.61B derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2018-12-31 | $335.50M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $882.30M derived: sum of 2 quarters · filed 2021-03-01 | $1.26B derived: sum of 3 quarters · filed 2021-03-01 | $1.59B 10-K · filed 2021-03-01 | ||||
| 2018-09-29 | $546.80M 10-Q · filed 2019-11-06 | $923.10M derived: sum of 2 quarters · filed 2019-11-06 | $1.26B 10-Q · filed 2019-11-06 | $1.61B derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-06-30 | $376.30M 10-Q · filed 2019-08-08 | $712.80M 10-Q · filed 2019-08-08 | $1.07B derived: sum of 3 quarters · filed 2020-02-27 | $1.40B derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-03-31 | $336.40M 10-Q · filed 2019-05-09 | $690.60M derived: sum of 2 quarters · filed 2020-02-27 | $1.03B derived: sum of 3 quarters · filed 2020-02-27 | $1.38B derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2017-12-31 | $354.20M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $689.60M derived: sum of 2 quarters · filed 2020-02-27 | $1.05B derived: sum of 3 quarters · filed 2020-02-27 | $1.38B 10-K · filed 2020-02-27 | ||||
| 2017-09-30 | $335.40M 10-Q · filed 2018-11-08 | $691.20M derived: sum of 2 quarters · filed 2018-11-08 | $1.03B 10-Q · filed 2018-11-08 | $2.00B derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-07-01 | $355.80M 10-Q · filed 2018-08-09 | $691.60M 10-Q · filed 2018-08-09 | $1.66B derived: sum of 3 quarters · filed 2019-02-27 | $3.62B derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-04-01 | $335.90M 10-Q · filed 2018-05-08 | $1.31B derived: sum of 2 quarters · filed 2019-02-27 | $3.26B derived: sum of 3 quarters · filed 2019-02-27 | $3.62B derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2016-12-31 | $972.30M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $2.93B derived: sum of 2 quarters · filed 2019-02-27 | $3.29B derived: sum of 3 quarters · filed 2019-02-27 | $4.05B 10-K · filed 2019-02-27 | ||||
| 2016-10-01 | $1.95B 10-Q · filed 2017-11-09 | $2.02B 10-Q · filed 2016-11-10 | $2.31B derived: sum of 2 quarters · filed 2017-11-09 | $3.08B 10-Q · filed 2017-11-09 | $3.18B 10-Q · filed 2016-11-10 | $3.73B derived: sum of 4 quarters · filed 2018-03-01 | ||
| 2016-07-02 | $361.70M 10-Q · filed 2017-08-10 | $328.90M 10-Q · filed 2016-08-10 | $1.13B 10-Q · filed 2017-08-10 | $1.16B 10-Q · filed 2016-08-10 | $1.78B derived: sum of 3 quarters · filed 2018-03-01 | $2.14B derived: sum of 4 quarters · filed 2018-03-01 | ||
| 2016-04-02 | $764.70M 10-Q · filed 2017-05-30 | $826.70M 10-Q · filed 2016-05-16 | $1.42B derived: sum of 2 quarters · filed 2018-03-01 | $1.78B derived: sum of 3 quarters · filed 2018-03-01 | $2.18B derived: sum of 4 quarters · filed 2018-03-01 | |||
| 2015-12-31 | $651.40M derived: 10-K 6 month − 10-Q/A 3 month · filed 2018-03-01 | $1.01B 10-K · filed 2018-03-01 | $1.01B 10-KT · filed 2016-02-25 | $1.42B derived: sum of 3 quarters · filed 2018-03-01 | $1.60B derived: sum of 4 quarters · filed 2018-03-01 | |||
| 2015-09-26 | $359.90M 10-Q/A · filed 2017-05-23 | $360.20M 10-Q · filed 2015-11-02 | $768.60M derived: sum of 2 quarters · filed 2017-05-23 | $947.60M 10-Q/A · filed 2017-05-23 | $941.00M 10-Q · filed 2016-11-10 | $1.15B derived: sum of 4 quarters · filed 2017-05-23 | ||
| 2015-06-27 | $408.70M 10-Q/A · filed 2017-05-22 | $401.20M 10-Q · filed 2016-08-10 | $587.70M 10-Q/A · filed 2017-05-22 | $580.80M 10-Q · filed 2016-08-10 | $787.10M derived: sum of 3 quarters · filed 2017-05-22 | $971.70M 10-K · filed 2018-03-01 | $964.80M 10-K · filed 2015-08-13 | |
| 2015-03-28 | $179.00M 10-Q/A · filed 2017-05-22 | $179.60M 10-Q · filed 2015-04-29 | $378.40M derived: sum of 2 quarters · filed 2017-05-22 | $563.60M 10-Q · filed 2015-04-29 | $781.30M derived: sum of 4 quarters · filed 2017-05-22 | |||
| 2014-12-27 | $199.40M 10-Q · filed 2015-02-05 | $384.10M 10-K · filed 2018-03-01 | $384.00M 10-Q · filed 2015-02-05 | $602.30M derived: sum of 3 quarters · filed 2017-05-22 | $814.00M derived: sum of 4 quarters · filed 2017-05-22 | |||
| 2014-09-27 | $184.60M 10-Q · filed 2015-11-02 | $402.90M derived: sum of 2 quarters · filed 2017-05-22 | $614.60M derived: sum of 3 quarters · filed 2017-05-22 | $888.70M derived: sum of 4 quarters · filed 2017-05-22 | ||||
| 2014-06-28 | $218.30M derived: 10-K 12 month − 10-Q 9 month · filed 2017-05-22 | $430.00M derived: sum of 2 quarters · filed 2017-05-22 | $704.10M derived: sum of 3 quarters · filed 2017-05-22 | $880.70M 10-K · filed 2017-05-22 | ||||
| 2014-03-29 | $211.70M 10-Q · filed 2015-04-29 | $485.80M derived: sum of 2 quarters · filed 2015-04-29 | $662.40M 10-Q · filed 2015-04-29 | $838.50M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2013-12-28 | $274.10M 10-Q · filed 2015-02-05 | $450.80M 10-Q · filed 2015-02-05 | $626.80M derived: sum of 3 quarters · filed 2016-02-25 | $779.60M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2013-09-28 | $176.60M 8-K · filed 2014-11-20 | $4.01K 10-Q · filed 2013-11-04 | $352.70M derived: sum of 2 quarters · filed 2016-02-25 | $505.50M derived: sum of 3 quarters · filed 2016-02-25 | $648.80M derived: sum of 4 quarters · filed 2016-02-25 | |||
| 2013-06-29 | $176.10M derived: 10-KT 12 month − 10-Q 9 month · filed 2016-02-25 | $328.90M derived: sum of 2 quarters · filed 2016-02-25 | $472.20M derived: sum of 3 quarters · filed 2016-02-25 | $600.90M 10-KT · filed 2016-02-25 | ||||
| 2013-03-30 | $152.80M 10-Q · filed 2014-05-07 | $296.10M derived: sum of 2 quarters · filed 2014-05-07 | $424.80M 10-Q · filed 2014-05-07 | |||||
| 2012-12-29 | $143.30M 10-Q · filed 2014-02-06 | $272.00M 10-Q · filed 2014-02-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |